How GSK Is Driving Early Stage Research In Its DPUs
Most of GlaxoSmithKline's early stage research organizations, discovery performance units, survive a three-year review cycle, with co-localization, monetary incentives and career support leading a change of culture.
You may also be interested in...
GlaxoSmithKline’s DPU model is industry’s most radical attempt to apply the lessons – and the pressures – of working in small biotech environments. BD and biopharma head Ian Tomlinson discusses what went wrong, and what GSK thinks it’s now doing right.
During a nearly two-hour R&D seminar, executives at GlaxoSmithKline PLC described the company's evolving strategy, detailing the organization's goals, capital allocation, and productivity performance, and providing a glimpse into the ongoing work within six of its 40 biotech-like discovery performance units.
At its latest R&D review, GSK has culled three of its biotech-like discovery performance units and created four new ones. But less important than the numbers is the new culture, claims CEO Andrew Witty